A Randomized Phase II Study of Epigenetic Therapy With Azacitidine and Entinostat With Concurrent Nivolumab Versus Nivolumab Alone in Subjects With Recurrent Metastatic Non-Small Cell Lung Cancer.
Phase of Trial: Phase II
Latest Information Update: 26 Apr 2017
At a glance
- Drugs Entinostat (Primary) ; Nivolumab (Primary) ; Azacitidine; Azacitidine
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 10 Nov 2016 Planned End Date changed from 1 Aug 2016 to 1 Aug 2018.
- 10 Nov 2016 Planned primary completion date changed from 1 Aug 2016 to 1 Aug 2017.
- 08 Nov 2016 Results from this trial will be presented at the Society for Immunotherapy in Cancer (SITC) 31st Annual Scientific Meeting 2016, according to a Syndax Pharmaceuticals media release.